XML 79 R62.htm IDEA: XBRL DOCUMENT
v3.25.3

Convertible Notes Receivable, Due from Cyclo Therapeutics, LLC. (Details) - USD ($) $ / shares in Units, $ in Millions |  |  |  |  |  |  |  |  |  |  |  |  | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 06, 2025 | Feb. 04, 2025 | Jan. 03, 2025 | Dec. 23, 2024 | Dec. 21, 2024 | Dec. 05, 2024 | Nov. 07, 2024 | Oct. 08, 2024 | Sep. 09, 2024 | Aug. 21, 2024 | Jul. 16, 2024 | Jun. 11, 2024 | Jul. 31, 2025 | Mar. 25, 2025
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding principal and accrued interest |  |  |  | $ 2.5 |  |  |  |  |  |  |  |  | $ 30.6 |
Common stock, shares issued (in Shares) |  |  |  | 3,968,254 |  |  |  |  |  |  |  |  |  | 12,998,194
Common stock, par value (in Dollars per share) |  |  |  | $ 0.63 |  |  |  |  |  |  |  |  |  |
Cyclo Convertible Note I [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  |  |  |  |  |  | $ 2.0 |  |
Notes received in cash |  |  |  |  |  |  |  |  |  |  |  | $ 2.0 |  |
Maturity date |  |  |  |  |  |  |  |  |  |  |  | Mar. 31, 2025 |  |
Interest rate |  |  |  |  |  |  |  |  |  |  |  | 5.00% |  |
Cyclo Convertible Note II [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  |  |  |  |  | $ 2.0 |  |  |
Notes received in cash |  |  |  |  |  |  |  |  |  |  | $ 2.0 |  |  |
Maturity date |  |  |  |  |  |  |  |  |  |  | Mar. 31, 2025 |  |  |
Interest rate |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  |
Cyclo Convertible Note III [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  |  |  |  | $ 3.0 |  |  |  |
Notes received in cash |  |  |  |  |  |  |  |  |  | $ 3.0 |  |  |  |
Maturity date |  |  |  |  |  |  |  |  |  | Mar. 31, 2025 |  |  |  |
Interest rate |  |  |  |  |  |  |  |  |  | 5.00% |  |  |  |
Common stock, percentage |  |  |  |  |  |  |  |  |  | 49.90% |  |  |  |
Cyclo Convertible Note IV [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  |  |  | $ 3.0 |  |  |  |  |
Notes received in cash |  |  |  |  |  |  |  |  | $ 3.0 |  |  |  |  |
Maturity date |  |  |  |  |  |  |  |  | Mar. 31, 2025 |  |  |  |  |
Interest rate |  |  |  |  |  |  |  |  | 5.00% |  |  |  |  |
Cyclo Convertible Note [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  | Feb. 15, 2025 |  |  |  |  |  |  |  |  |
Common stock, percentage | 49.90% | 49.90% | 49.90% |  |  | 49.90% | 49.90% | 49.90% | 49.90% |  |  |  |  |
Cyclo Convertible Note V [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  |  | $ 3.0 |  |  |  |  |  |
Notes received in cash |  |  |  |  |  |  |  | $ 3.0 |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  | Mar. 31, 2025 |  |  |  |  |  |
Interest rate |  |  |  |  |  |  |  | 5.00% |  |  |  |  |  |
Cyclo Convertible Note VI [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  | $ 2.0 |  |  |  |  |  |  |
Notes received in cash |  |  |  |  |  |  | $ 2.0 |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  | Mar. 31, 2025 |  |  |  |  |  |  |
Interest rate |  |  |  |  |  |  | 5.00% |  |  |  |  |  |  |
Cyclo Convertible Note VII [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  | $ 1.0 |  |  |  |  |  |  |  |
Notes received in cash |  |  |  |  |  | $ 1.0 |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  | Mar. 31, 2025 |  |  |  |  |  |  |  |
Interest rate |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |
Cyclo Convertible Note VIII [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  | $ 3.0 |  |  |  |  |  |  |  |  |  |  |
Notes received in cash |  |  | $ 3.0 |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  | Mar. 31, 2025 |  |  |  |  |  |  |  |  |  |  |
Interest rate |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |
Cyclo Convertible Note IX [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  | $ 2.0 |  |  |  |  |  |  |  |  |  |  |  |
Notes received in cash |  | $ 2.0 |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  | Mar. 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |
Interest rate |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |
Cyclo Convertible Note X [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount | $ 2.5 |  |  |  |  |  |  |  |  |  |  |  |  |
Notes received in cash | $ 2.5 |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date | Mar. 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Note Purchase Agreement [Member] | Cyclo Convertible Note I [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  |  |  |  |  | Nov. 11, 2024 |  |
First Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note II [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  |  |  |  | Nov. 11, 2024 |  |  |
Second Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note III [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  |  |  | Dec. 21, 2024 |  |  |  |
Third Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note IV [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  |  | Dec. 21, 2024 |  |  |  |  |
Fourth Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note V [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  | Dec. 21, 2024 |  |  |  |  |  |
Fifth Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note VI [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  | Dec. 21, 2024 |  |  |  |  |  |  |
Sixth Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note VII [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  | Dec. 21, 2024 |  |  |  |  |  |  |  |
Seventh Amended and Restated Note Purchase Agreement [Member] | Cyclo Convertible Note VIII [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  | Feb. 15, 2025 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Outstanding principal and accrued interest. + References No definition available. + Details
Name: | rfl_OutstandingPrincipalAndAccruedInterest
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsNotesAndLoansReceivableLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_ConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details
Name: | us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase price of common stock expressed as a percentage of its fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteIIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteIIIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteVIIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteVIIIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_CycloConvertibleNoteXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_NotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_FirstAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_SecondAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_ThirdAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_FourthAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_FifthAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_SixthAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_SeventhAmendedAndRestatedNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |